Island Pharmaceuticals Ltd (AU:ILA)
ASX:ILA
Top Page
Island Pharmaceuticals Ltd
(Sydney:ILA)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.36
â–Ľ(-18.86% Downside)
Action:ReiteratedDate:03/05/26
The score is held down primarily by weak operating performance and continued cash burn, despite a clean, low-debt balance sheet. Technical indicators show subdued momentum, and valuation provides limited support given negative earnings and no dividend data.
Positive Factors
Low financial leverage
Zero reported debt and materially higher equity improve solvency and provide balance-sheet flexibility to fund R&D or withstand development cycles without high interest burdens. This reduces bankruptcy risk and preserves strategic options over the next several months.
Negative Factors
Sharp revenue decline
A roughly 70% year-over-year revenue collapse to about $119k indicates significant deterioration in commercial traction or one-off revenue loss. Such a structural decline undermines operating leverage, reduces internal funding capacity, and raises questions about sustainable revenue sources.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Zero reported debt and materially higher equity improve solvency and provide balance-sheet flexibility to fund R&D or withstand development cycles without high interest burdens. This reduces bankruptcy risk and preserves strategic options over the next several months.
Read all positive factors
Island Pharmaceuticals Ltd (ILA) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$109.32M
Dividend YieldN/A
Average Volume (3M)781.24K
Price to Earnings (P/E)―
Beta (1Y)-0.79
Revenue GrowthN/A
EPS Growth26.38%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding295,456,700
10 Day Avg. Volume388,484
30 Day Avg. Volume781,243
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)3.39
Price to Sales (P/S)204.10
P/FCF Ratio-8.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Island Pharmaceuticals Ltd Business Overview & Revenue Model
Company Description
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengu...
How the Company Makes Money
null...
Island Pharmaceuticals Ltd Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
66
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.07K | 118.91K | 1.25M | 11.06K | 0.00 | 0.00 |
| Gross Profit | -729.59K | -1.29M | -1.01M | 11.06K | 0.00 | 0.00 |
| EBITDA | -4.90M | 0.00 | -2.82M | -2.82M | -2.61M | -2.13M |
| Net Income | -7.20M | -3.92M | -2.86M | -2.83M | -2.61M | -2.13M |
Balance Sheet | ||||||
| Total Assets | 8.02M | 7.49M | 2.56M | 2.05M | 4.90M | 6.64M |
| Cash, Cash Equivalents and Short-Term Investments | 6.87M | 7.25M | 1.66M | 2.00M | 4.79M | 6.46M |
| Total Debt | 0.00 | 0.00 | 421.97K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 860.15K | 336.43K | 1.05M | 263.85K | 580.73K | 236.83K |
| Stockholders Equity | 7.16M | 7.16M | 1.52M | 1.79M | 4.32M | 6.40M |
Cash Flow | ||||||
| Free Cash Flow | -3.67M | -2.77M | -3.16M | -2.71M | -1.88M | -938.24K |
| Operating Cash Flow | -3.67M | -2.77M | -3.16M | -2.71M | -1.88M | -938.24K |
| Investing Cash Flow | -841.70K | 0.00 | 0.00 | 0.00 | 0.00 | 77.37K |
| Financing Cash Flow | 7.41M | 8.36M | 2.79M | -171.36K | 0.00 | 7.30M |
Island Pharmaceuticals Ltd Technical Analysis
Neutral
0.44
Price Trends
0.40
Negative
0.44
Negative
0.35
Positive
Market Momentum
-0.01
Positive
41.80
Neutral
18.75
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ILA, the sentiment is Neutral. The current price of 0.44 is above the 20-day moving average (MA) of 0.41, above the 50-day MA of 0.40, and above the 200-day MA of 0.35, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 41.80 is Neutral, neither overbought nor oversold. The STOCH value of 18.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:ILA.
Island Pharmaceuticals Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$71.24M | -7.57 | -179.37% | ― | ― | 16.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$197.36M | 27.58 | -15.96% | ― | -40.74% | -21.21% | |
43 Neutral | AU$109.32M | -5.66 | -100.58% | ― | ― | 26.38% | |
42 Neutral | AU$55.73M | -5.28 | -62.49% | ― | ― | 10.78% | |
42 Neutral | AU$23.61M | -5.38 | -19.10% | ― | ― | -672.73% | |
40 Underperform | AU$35.68M | -10.60 | -142.30% | ― | 110.44% | 35.90% |
* Healthcare Sector Average
AU:ILA
Island Pharmaceuticals Ltd
0.37
0.21
124.24%
AU:CYP
Cynata Therapeutics Limited
0.30
0.11
62.16%
AU:PTX
Prescient Therapeutics Limited
0.05
<0.01
12.77%
AU:SPL
Starpharma Holdings Limited
0.47
0.38
400.00%
AU:ADO
AnteoTech Ltd
0.01
0.00
0.00%
AU:NSB
Neuroscientific Biopharmaceuticals Ltd.
0.07
0.03
77.50%
Island Pharmaceuticals Ltd Corporate Events
Island Pharmaceuticals Issues New Shares on Option Conversion, Affirms Compliance
Mar 22, 2026
Island Pharmaceuticals has issued 690,000 fully paid ordinary shares following the exercise of unlisted options at an issue price of $0.21 per share. The move modestly increases the company’s share capital and reflects the conversion of exis...
Island Pharmaceuticals Seeks ASX Quotation for 690,000 New Shares
Mar 22, 2026
Island Pharmaceuticals Ltd has applied for quotation on the ASX of 690,000 new ordinary fully paid shares, to be traded under its existing ticker ILA. The new securities, issued on March 23, 2026, modestly expand the company’s listed share b...
Island Pharmaceuticals Halts Trading Ahead of Biodefence Deal Announcement
Mar 1, 2026
Island Pharmaceuticals has requested a trading halt in its shares on the ASX, effective from the start of trading on 2 March 2026. The halt will remain in place until either the commencement of normal trading on 4 March 2026 or the earlier release...
Island Pharmaceuticals posts wider half-year loss despite uptick in asset backing
Feb 25, 2026
Island Pharmaceuticals Limited reported a sharp increase in its half-year loss for the period ended 31 December 2025, with the loss after tax widening to $4.81 million from $1.53 million a year earlier. Despite the deeper loss, net tangible assets...
Island Pharmaceuticals Defends Handling of FDA Feedback in ASX Query
Feb 10, 2026
Island Pharmaceuticals has responded to an ASX price query, confirming that recent feedback from the U.S. Food and Drug Administration on the development pathway for its antiviral candidate Galidesivir was materially price-sensitive. The company d...
Island Pharmaceuticals Outlines Strategy on Urgent Viral Threats in Investor Presentation
Feb 5, 2026
Island Pharmaceuticals Limited has released an investor-focused presentation outlining its activities in combating urgent viral disease threats and providing an overview of its business and risk profile. The document emphasises that the material i...
Island Pharmaceuticals Plans New Share Placement to Raise Capital
Feb 3, 2026
Island Pharmaceuticals Limited has announced a proposed placement of up to 25,714,285 new fully paid ordinary shares, with an expected issue date of 16 February 2026. The equity raising, to be quoted on the ASX under the company’s existing c...
Island Pharmaceuticals Raises A$9m to Accelerate Galidesivir Biodefence Program and US Stockpile Push
Feb 3, 2026
Island Pharmaceuticals has raised A$9 million via a placement of 25.7 million new shares at A$0.35 each, cornerstoned by a US-based family office and supported by other local and international investors, extending its cash runway from an existing ...
FDA Backs Island Pharmaceuticals’ Galidesivir Pathway, Opening Route to Accelerated Approval
Feb 3, 2026
Island Pharmaceuticals has secured key guidance from the US Food and Drug Administration validating its proposed animal model for Galidesivir and setting out a two-stage development pathway under the FDA’s Animal Rule, a milestone the compan...
Island Pharmaceuticals Requests Trading Halt Ahead of FDA Feedback on Galidesivir
Feb 1, 2026
Island Pharmaceuticals Ltd has requested and been granted a trading halt on its ordinary shares on the ASX, effective from the start of trading on 2 February 2026, as it prepares to release an announcement related to US FDA feedback on its Galides...
Island Pharmaceuticals Advances Clinical Programs Targeting Urgent Viral Threats
Jan 26, 2026
Island Pharmaceuticals reported that it is progressing two well-advanced clinical-stage programs targeting infectious diseases, highlighted by the completion of its Phase 2a/b PROTECT clinical trial in dengue. Both assets are positioned for major ...
Island Pharmaceuticals Secures Key FDA Boost and US Partnerships for Galidesivir Antiviral Program
Jan 26, 2026
Island Pharmaceuticals reported a strategically significant December 2025 quarter marked by substantial regulatory and operational progress for its Galidesivir antiviral program. The US FDA confirmed that Galidesivir is eligible for approval under...
Island Pharmaceuticals Issues 8 Million Unquoted Options as Part of Capital Structure
Jan 5, 2026
Island Pharmaceuticals Limited has notified the market of the issue of 8,000,000 unquoted options, described as options expiring on various dates and at various exercise prices, with an issue date of 12 November 2025. The new options, recorded via...
Island Pharmaceuticals Awaits Extended FDA Review as Galidesivir Preparations Advance
Jan 4, 2026
Island Pharmaceuticals has reported that the US Food Drug Administration has requested additional time to finalise its response on the regulatory development pathway for Galidesivir under the Animal Rule, but has not issued any adverse feedback, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.